Regeneron Pharmaceuticals, Inc. (REGN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Regeneron Pharmaceuticals, Inc. (REGN) is down 21.7% since the beginning of the year. At $603 per share, REGN is trading 26.6% below its 52-week high of $821. Investors who bought $1,000 worth of REGN shares 5 years ago would now be looking at an investment worth $1,202.

Regeneron Pharmaceuticals, Inc. (REGN) has returned -21.68% so far this year and 24.26% over the past 12 months. Over the last ten years, REGN has returned 4.25% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Apr 2, 1991, REGN's average daily return is +0.12%, while the average monthly return is +2.74%. At this rate, an investment would double in approximately 2.1 years.

Historically, 49% of months were positive and 51% were negative. The best month was Feb 2000 with a return of +359.0%, while the worst month was Mar 2003 at -59.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, REGN closed higher 47% of trading days. The best single day was Feb 23, 2000 with a return of +75.4%, while the worst single day was Mar 31, 2003 at -56.6%.

Regeneron Pharmaceuticals, Inc. has an annualized alpha of 20.10%, beta of 1.10, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since April 03, 1991.

• This stock captured 115.71% of S&P 500 Index gains and 110.15% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

REGN ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and compare them to S&P 500 Index.

Regeneron Pharmaceuticals, Inc. provided a 0.60% dividend yield over the last twelve months, with an annual payout of $3.64 per share.

The table displays the monthly dividend distributions for Regeneron Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Regeneron Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Regeneron Pharmaceuticals, Inc. was 91.81%, occurring on Apr 14, 2005. Recovery took 1520 trading sessions.

The current Regeneron Pharmaceuticals, Inc. drawdown is 49.42%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Regeneron Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Regeneron Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.